SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Heineken Q3 Organic Revenue and Volume Grow More Than 4%

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.

HEIA
SquawkNews Desk

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.

Related stories

Citi Cuts Suncorp Price Target After Premium Growth Forecast Trim Citi lowered its price target on Suncorp after the insurer trimmed its annual premium growth forecast. L impact | EQUITY | Oct 29, 2026, 11:01 PM UTC Richards Group Reports Third-Quarter 2026 Results Richards Group reported revenue growth of 2%, primarily from acquisitions, and gross margins up 7%. M impact | EQUITY | Oct 29, 2026, 11:00 PM UTC Global market picture: S&P 500 -1.08%, Nasdaq 100 -3.1%; EUR/USD +0.33%, WTI +0.05% Global market picture. US index futures: S and P futures is down 1.08 percent, Nasdaq futures is down 3.1 percent, Dow futures is down 0.4 percent and Russell futures is up 0.92 pe M impact | EQUITY | Oct 29, 2026, 11:00 PM UTC Mapletree Pan Asia Commercial Trust Q2 Adjusted Revenue SGD 207.483 Million M impact | EQUITY | Oct 29, 2026, 10:58 PM UTC Twilio Raises Full-Year Revenue Growth Outlook to 20% After Higher 3Q Profit Twilio said it now expects full-year revenue growth of 20%, up from its previous outlook of 18% to 18.5%, after reporting higher profit and revenue growth in the third quarter. M impact | EQUITY | Oct 29, 2026, 10:57 PM UTC Hanmi Pharmaceutical Licenses Fabry Disease Therapy to BioMarin for $237.5 Million Hanmi Pharmaceutical licensed its Fabry disease therapy to BioMarin in a deal valued at USD 237.5 million. M impact | EQUITY | Oct 29, 2026, 10:55 PM UTC